Trial Profile
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Nov 2020
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Fludarabine; Interferon; Methylprednisolone; Mitoxantrone; Prednisone; Procarbazine; Vincristine
- Indications B-cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 25 Aug 2017 Status changed from active, no longer recruiting to completed.
- 12 Sep 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 08 Sep 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017 as reported by ClinicalTrials.gov